Introduction

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an

integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranked 8th amongst the global generic pharmaceutical companies, Ranbaxy today has a presence in 23 of the top 25 pharmaceutical markets of the world. The Company has a global footprint in 49 countries, world-class manufacturing facilities in 11 countries and serves customers in over 125 countries. Ranbaxy was incorporated in 1961 and went public in 1973. For the year 2008, the Company recorded Global Sales of US $ 1,682 Mn, reflecting a growth of 4%. The Company has a balanced mix of revenues from emerging and developed markets that contribute 54% and 39% respectively. In 2008, North America, the Companys largest market contributed sales of US $ 449 Mn, followed by Europe garnering US $ 330 Mn. Business in Asia has been going strong with India clocking sales of around US $ 300 Mn with market leadership in several business segments, backed by strong brand-building skills. In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator companies, Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical powerhouse. The combined entity now ranks among the top 15 pharmaceutical companies, globally. The transformational deal will place Ranbaxy in a higher growth trajectory and it will emerge stronger in terms of its global reach and in its capabilities in drug development and manufacturing.

Company profile
Ranbaxy Laboratories Ltd. is the largest pharmaceutical company in India and one of the worlds top 100 pharmaceutical companies. Ranbaxy is specialist in the preparation of generic drugs; Ranbaxy is also one of the world top 10 in that pharmaceutical category as well, with India's agreement to apply international patent law at the beginning of 2005, Ranbaxy has begun converting itself into a full-fledged research-based pharmaceutical company. A major part of this effort has been the establishment of the company's own research and development center, which has enabled the company to begin to enter the new chemical entities NCE) and novel drug delivery systems (NDDS) markets. In November 2008, Daiichi Sankyo completed the acquisition of 63.92% shares of Ranbaxy and in the process infused. The coming together of Ranbaxy and Daiichi Sankyo is a path-breaking confluence that, in one sweep, catapults the

new, empowered entity to the status of the world's 15th largest pharmaceutical Company. Individually, the two pharmaceutical giants are formidable - one, India's largest generics Company and the other, among the largest innovator companies in Japan. Ranbaxy is a truly global operation, producing its pharmaceutical preparations in manufacturing facilities in seven countries, supported by sales and marketing subsidiaries in 44 countries, reaching more than 100 countries throughout the world. The United States, which alone accounts for nearly half of all pharmaceutical sales in the world, is the company's largest international market, representing more than 40 percent of group sales. In Europe, the company's purchase of RPG (Aventis) S.A. makes it the largest generics producer in that market. The company is also a leading generics producer in the United Kingdom and Germany and elsewhere in Europe. European sales added 16 percent to the company's sales in 2004. Ranbaxy's other major markets include Brazil, Russia, and China, as well as India, which together added 26 percent to the group's sales.

Vision & Mission

The Indian pharmaceutical industry is at the center stage in the global Pharmaceutical arena and Ranbaxy is at the forefront in delivering the India centric advantages to the advanced and developing countries of the world. The Endeavour at Ranbaxy is to provide value. Value through pioneering work, research & development and quality pharmaceuticals across the globe. Ranbaxy keeps alive this Endeavour as it steps into the new millennium, and reaffirms its commitment to the environment, the people and a healthier future. Ranbaxy Laboratories Limited has excelled in its endeavor in drug research and manufacture, providing quality products not only at par with global markets but also facilitating the same. Ranbaxy are committed to provide quality generics at affordable prices to the patients worldwide with a view to help bring down the healthcare costs. Companies grow from strength to strength in the global generic space in the years to come. While the company continues to enhance the momentum of generics business in over 125 markets, they are also accelerating drug discovery program through collaborations and alliances. Ranbaxy is driven by its vision to achieve significant business in proprietary prescription products by 2012 with a strong presence in developed markets. The

Company aspires to be amongst the Top 5 global generic players and aims at achieving global sales of US $5 Bn by 2012.

Company Strategies
For the year 2009, Ranbaxy has a clear strategy to harness its growth potential in emerging markets, rebuild the US business through a series of actions on products and facilities; actualize significant revenue upsides through First-to-File and Day1 launches strengthen the product / therapeutic pipeline and look for M&A opportunities, complementing our geographic and therapeutic basket. Our focus will be to resolve regulatory compliance issues and continue to strengthen cGMP across all locations. Besides this, Ranbaxy and Daiichi Sankyo will identify key projects to realize synergies at both the front and back ends of the business, although, there will be much to contend with, considering that the industry is projected to grow at around 5% in 2009.
Ranbaxy is focused on increasing the momentum in the generics business in its key markets through organic and inorganic growth routes. The Company continues to evaluate acquisition opportunities in India, emerging and developed markets to strengthen its business and competitiveness. Growth is well spread across geographies with focus on emerging markets. Ranbaxy has forayed into new specialty therapeutic segments like Bio-similars, Oncology, Peptides and Limuses. These new growth areas will add significant depth to the existing product pipeline.

Company Growth
Consolidated net sales at Rs. 18,884 Mn, a growth of 14% (USD 431 Mn). Emerging markets portfolio achieves sales of Rs. 10,644 Mn, with a strong growth of 20%; accounts for 56% of sales (USD 243 Mn). Developed markets sales grew by 9% to Rs. 7,089 Mn (USD 162 Mn); accounts for 38% of sales. Earnings before Interest, Tax, Depreciation & Amortization (EBITDA) for the quarter are Rs. 1,440 Mn (8%). EBITDA for the year to date is Rs. 7,253 Mn reflecting a margin to sales of 14%. Gross margin on year to date basis maintained at 51% despite adverse economic conditions this year. Over the current year there has been a consistent improvement in Working Capital management with a result that the Companys Gross Working Capital has reduced by 5%.

Competitors
The pharmaceutical industry is characterized by rapid advances in scientific knowledge and ability to discover new drugs. The industry is therefore led by large manufacturers and marketers of drugs investing heavily in research &development, having clinical testing, marketing and distributing capabilities. Some of the main competitors of Ranbaxy are:

Sun Pharmaceuticals Industries - It is No. 1 in India in specialty therapy

areas like psychiatry, neurology, cardiology, gastroenterology, diabetology and respiratory.[.It has brands in 30 markets worldwide and also has a generic presence in the U.S. with Caraco Pharm Labs, Sun Pharmaceutical Industries Inc

Cipla - Cipla is a leader in the domestic retail pharmaceutical market. It also exports raw materials, intermediates, prescription drugs, over-the-counter products, and veterinary products to some 180 countries around the world.

Glaxo smith Kline- It is one of the oldest pharma companies in India and

with a turnover of Rs. 1500 crore is one of the market leaders(market share) in India with a share of 6.2 per cent Its main portfolios consists of antiinvectives, dermatologicals and pain management drugs

Dr.Reddys Laboratories It is a global pharmaceutical company with it's headquarters in India and a presence in more than 100 countries. In India it the biggest drug maker by sales. Other competitors areActavis,Sandoz International GmbH; Teva pharmaceuticals,RPG Enterprises, , East India Pharmaceutical Works Ltd, Concept Pharmaceuticals Ltd, Khandelwal Laboratories Ltd, Dabur India Ltd.

Life at Ranbaxy

A career at Ranbaxy means an opportunity for ample learning & growth. It 0ffers avenues to work across the globe along side the finest minds. The company offers a challenging assignment, a world class working environment, professional management, competitive salaries and stock options along with exceptional rewards. Opportunities The global spread of Ranbaxy and the blazing growth in business provides ample opportunities for employees to build careers in various fields. Opportunities have never been a constraint for the deserving. The company believes in employee growth that goes beyond vertical movements and change in designations. Potential and performance are the pillars of career progression at Ranbaxy. A robust development process supports this. Managers will generally have the opportunity to live and work in different countries; such international experience will help them better understand our complex business and grow both personally and professionally

Salary and Benefits

Salaries and other benefits in Ranbaxy are comparable with the best in the industry and one can expect to be rewarded highly if the performance is consistently outstanding.

Group Life Insurance, Medical Insurance and Pension plans are a few examples of the benefits we provide to our employees and their dependents with adequate financial protection on long term basis.

Stock ownership
The ownership in business is fundamental to personal progression, company encourage you to take ownership of your investment stock ownership is a part of the compensation for managers early in their career at Ranbaxy you will see the business results straight in your pay slip.

Value and Activities

Corporate Social Responsibility (CSR)
As a global leader in pharmaceuticals Ranbaxy take pride not only in providing products that enable people to live healthier and fuller lives, but also in giving back to the society. At Ranbaxy, Corporate Social Responsibility and concern for Environment, Health and Safety are a part of the corporate DNA.Reaching out to the underserved rural communities and helping them overcome their challenges is central to Ranbaxy's CSR philosophy.

Environment
As a socially responsible company, Ranbaxy has made an enduring commitment to consistently set new benchmarks in environmental protection and workplace. The Company is also deeply aware of its responsibility to deploy clean and green technologies that help in providing a sustainable environment. This further builds upon the already significant bond of trust and concern that it warmly shares with the communities located in and around its operating facilities. The Environmental Management System (EMS) at key API manufacturing facilities at Toansa and Mohali, in Punjab, went through the annual surveillance audit, by a leading external verifying agency both manufacturing facilities conformed to all audit specifications and continued to remain ISO14001 complaint.

Notable progress was made towards achieving the defined environmental objectives, programs and long-term goals. For further improving the wastewater management, an Agitated Thin Film Dryer and Plate type Ultra Filtration were added as incremental safeguards, at the Toansa API facility.

Health
Company always strives to make a meaningful impact on the quality of their lives by bringing preventive, promotive and curative healthcare services to their doorstep. Nearly three decades ago in 1979, Ranbaxy started its health care initiatives in certain identified rural areas of Punjab. As the reach of the program grew, the Ranbaxy Community Health Care Society (RCHS) was established in 1994. A novel idea of providing mobile health care outreach service for the poor and underprivileged was initiated. The program today benefits nearly 2 lakh people in 77 rural and urban slum areas in Punjab, Haryana, Himachal Pradesh, Madhya Pradesh and Delhi. Today, six well equipped mobile health care vans with teams of medics and paramedics are actively engaged in the delivery of health care to our target population in these states. The issues addressed include maternal-child health, family planning, reproductive health, adolescent health, health education and AIDS awareness.

Safety

It is constant endeavour to scale up and better safety practices. A number of initiatives were undertaken to enhance workplace safety. The emergency preparedness was ensured through regular tabletop exercises and mock drills at all our manufacturing facilities and R&D centres. At Toansa manufacturing facility, the 'Fire and Safety Risk Assessment' and the 'Hazardous Area Classification' was reviewed by third party specialists. The National Safety Council also conducted external safety audits at Toansa and Mohali. A crossfunctional team of Corporate EHS, Engineering and Facility professionals along with an external specialist further undertook external safety audits at the Corporate Office. Extensive safety training programs were also conducted by internal and external specialists at all manufacturing facilities, including those managed by contract

Declaration
I hereby declare that this company analysis report of RANBAXY submitted by me to the department of business administration is a bonafide work undertaken by me and it is not submitted to any other university or institution by any other person for the award of any degree diploma /certificate or published any time before.

Place: Date:

Name Manish Verma MBA